Severe Hemophilia A
Conditions
Keywords
ITI, Haemophilia A, Inhibitors, Failed ITI, VWF/FVIII concentrates
Brief summary
The purpose of this study is to evaluate whether a concentrate containing both FVIII and von Willebrand Factor (VWF) given at a high dose will induce immune tolerance in subjects who have already experienced and failed ITI with VWF-free FVIII concentrates. The treatment on this study is expected to last up to 33 months.
Detailed description
The presence of Factor VIII (FVIII) inhibitor prevents FVIII infusions from working properly and makes treatment of bleeding episodes very difficult. Having an inhibitor is a serious and life-threatening complication in patients with Hemophilia. The usual treatment of patients with FVIII inhibitors involves what is called immune tolerance induction (ITI). Immune Tolerance means that the body can accept infused FVIII and that FVIII is again effective in controlling bleeds. ITI involves giving high doses of FVIII regularly until the inhibitor disappears. This treatment is not always effective. The inhibitor persists in about 1 in 5 patients who undergo ITI. There are 2 types of FVIII concentrates: FVIII concentrates derived from human plasma, which contain VWF, and concentrates of FVIII without VWF. Both types of concentrates are commonly used to induce immune tolerance in patients with Hemophilia A. Retrospective studies on subjects who were treated with VWF containing Factor VIII concentrates after failing ITI with pure factor VIII concentrates, have shown that tolerance can be achieved in a large percentage of patients. This study will access prospectively whether treatment with a FVIII concentrate containing VWF given at a high dose (200 units per kilogram) daily for up to 33 months is able to induce immune tolerance after previous attempts with concentrates containing only FVIII have failed.
Interventions
DRUGVWF/FVIII concentrates
200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
Sponsors
Charta Foundation
Grifols Biologicals, LLC
CSL Behring
Biotest Pharmaceuticals Corporation
Grifols Therapeutics LLC
City of Hope Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
1. severe hemophilia A (FVIII\<1%) with high responding inhibitors (peak levels \>5 BU) 2. male, any age; 3. any inhibitor level at study enrollment; 4. ability and willingness to participate to the study; 5. previous ITI course of at least 9 months with a VWF-free FVIII concentrate at any dosage, such as recombinant FVIII and/or monoclonally purified FVIII.
Exclusion criteria
1. concomitant systemic treatment with immunosuppressive drugs; 2. concomitant experimental treatment; 3. previous history of myocardial infarction and/or cerebral stroke
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Achievement of an inhibitor titer of <0.6 BU/failure to achieve an inhibitor titer of <0.6 BU within 33 months, or failure to decrease inhibitor titer by at least 20% compared to titer in prior 6 months, beginning at 3 months after starting ITI | 3 years | Primary end point is the achievement of an inhibitor titer of less than 0.6 BU or failure to achieve an inhibitor titer of less than 0.6 BU within 33 months of treatment, or failure to decrease the inhibitor titer by at least 20% compared to the titer in the prior 6 months, beginning at 3 months after starting ITI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to achieve success- either partial or complete. | 33 months | — |
| Safety - assessment of adverse events through treatment and compliance with prolonged regimen. | 33 months | Includes assessment and evaluation of adverse events occurring through treatment and compliance with a lengthy regimen |
| Cost of care. | Up to 45 months | Direct cost will be calculated |
Countries
United States
Outcome results
None listed